Market News / Story
FTH — PIKTOR’s multi-node PAM strategy faces its key clinical test in endometrial cancer later in 2026
Quartr ·
Quartr reports: PIKTOR combines PI3Kα and mTORC1/2 inhibition to target a broad PAM-altered population, with management citing preclinical and early clinical activity plus tolerability data. PIK-201 top-line results are expected later in 2026, followed by initial PIK-101 data by year-end 2027. Based on Faeth Therapeutics, Inc. [FTH] KOL event Audio Transcript — Oct. 6 2026 This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original…